Mounjaro adverse side effects: what clinical data and UK guidance tell us

What the trial data recorded about how common these effects are

In SURMOUNT-1, published in the New England Journal of Medicine, nausea was reported by roughly 30–40% of participants on active treatment at the higher doses, with vomiting and diarrhoea following behind. The pattern is consistent across the broader tirzepatide clinical programme: effects tend to peak soon after starting or stepping up a dose, then diminish as the body adjusts. The NHS tirzepatide medicines page lists the same hierarchy: nausea, vomiting, diarrhoea, constipation, indigestion, burping, and fatigue at the top; injection-site reactions, headache, and dizziness further down.

One misconception worth naming here: many people assume that because a side effect is common it must be severe. The evidence doesn't bear that out. GI effects are frequent, yes, but most are described in trials as mild to moderate and transient. If you are curious about what happens when your body tolerates the medication particularly well, our page on experiencing no side effects on Mounjaro covers what that can mean and whether it should concern you. Severe effects do occur in a smaller proportion of people, and those are the ones that warrant a proper response, outlined below.

Tirzepatide carries a Black Triangle designation from the MHRA, meaning it is subject to additional monitoring while longer-term data accumulates. That is standard for newer medicines and does not signal unusual danger — it signals rigour. For a fuller breakdown of individual dose-specific patterns, our Mounjaro side effects overview goes into more detail.

Serious adverse effects: the signals that need same-day medical attention

Most side effects from Mounjaro are uncomfortable rather than dangerous. A smaller number require you to act quickly.

Acute pancreatitis is the one to know. In January 2026, the MHRA issued a Drug Safety Update confirming pancreatitis as a known, infrequent but potentially serious adverse effect of GLP-1 medicines including tirzepatide. The symptom to recognise is severe, persistent stomach pain that radiates toward the back, sometimes accompanied by vomiting. If that happens, stop taking Mounjaro and get medical help the same day, do not wait to see whether it passes.

Other warning signs that need prompt attention include: signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat); gallbladder problems, which can present as upper-right abdominal pain with fever; and dehydration from prolonged vomiting or diarrhoea, which can strain the kidneys. Our guide to the most clinically significant side effect of Mounjaro explains each of these in greater depth, and the NHS guidance on tirzepatide lists these clearly alongside the medicines information leaflet in every pen pack, read both before your first injection.

If you are unsure whether what you're experiencing needs urgent care, call 111. If symptoms are severe, call 999 or go to A&E.

Managing the more common adverse effects day to day

Nausea tends to be worse on an empty stomach. Eating smaller amounts at regular intervals, avoiding rich or fatty foods, and keeping well hydrated all help. Constipation responds to increased water intake and dietary fibre. These are not dramatic changes, but they make a real difference for most people working through the first weeks on a new dose.

Diarrhoea can occasionally be more disruptive. A small number of people find it severe enough to affect daily life, and there is detailed guidance on managing severe diarrhoea on tirzepatide if that applies to you. For a practical look at what to watch for as you move through the escalation schedule, our page on the side effects you may encounter if taking Mounjaro gives dose-by-dose context that many people find reassuring. The broader message is that most adverse effects respond well to the slower dose-escalation schedule already built into the treatment, a fact worth holding onto when the early weeks feel rough.

Injection-site reactions (redness, bruising, itching) are generally mild and improve with technique: rotating sites between abdomen, thigh, and upper arm, and allowing the pen to come to room temperature before injecting. Your prescriber can advise on technique; so can the Patient Information Leaflet supplied with every pen.

For people who find the idea of an injection a barrier, it is worth knowing that other licensed treatment options exist, including an oral format, and those can be discussed during a consultation.

Reporting side effects and getting ongoing support

If you experience a side effect you didn't expect, or one that concerns you, two routes exist. First, contact the clinical team supporting your treatment, at nume, our prescribers are available seven days a week through our aftercare service, and you can reach us via the contact page. Second, report it to the MHRA directly using the Yellow Card scheme, which exists specifically to capture real-world safety data on medicines like tirzepatide. Our page on the 5 Mounjaro side effects most commonly reported by patients offers a useful reference when you are deciding whether something is worth logging. Your report genuinely matters: the MHRA's ongoing monitoring depends on patients and clinicians filing them.

The NHS tirzepatide page also carries a clear list of which side effects to report to a pharmacist or GP and which require emergency care. Bookmark it alongside the leaflet in your pen pack.

If you have questions about whether Mounjaro is suitable for you given your own health history, our prescribers discuss suitability and side effects as part of every consultation. Speak to our prescribers to start that conversation, there is no charge for the consultation itself.